HLS Therapeutics (TSE:HLS) Hits New 12-Month Low – What’s Next?

HLS Therapeutics Inc. (TSE:HLS)’s stock price hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as C$3.71 and last traded at C$3.75, with a volume of 37404 shares traded. The stock had previously closed at C$3.90.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on HLS shares. Canaccord Genuity Group raised shares of HLS Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 13th. Raymond James Financial raised shares of HLS Therapeutics from an “outperform” rating to a “strong-buy” rating and upped their target price for the company from C$7.00 to C$8.00 in a report on Friday, August 14th. One investment analyst has rated the stock with a Strong Buy rating and one has given a Buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Strong Buy” and a consensus price target of C$8.00.

HLS Therapeutics Stock Down 1.8%

The company has a quick ratio of 1.01, a current ratio of 1.05 and a debt-to-equity ratio of 75.86. The company has a fifty day simple moving average of C$4.18 and a 200-day simple moving average of C$4.39. The firm has a market cap of C$118.84 million, a P/E ratio of -14.07 and a beta of -0.18.

HLS Therapeutics (TSE:HLS) last posted its quarterly earnings data on Wednesday, August 12th. The company reported C($0.03) EPS for the quarter. HLS Therapeutics had a negative return on equity of 14.39% and a negative net margin of 15.26%.The company had revenue of C$14.67 million during the quarter. During the same quarter in the prior year, the business earned ($0.09) earnings per share. On average, equities analysts anticipate that HLS Therapeutics Inc. will post -0.12 earnings per share for the current year.

HLS Therapeutics Company Profile

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.